Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MGP Panel: a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients

ABSTRACT: We designed a comprehensive multiple myeloma (MM) targeted sequencing panel to identify common genomic abnormalities in a single assay and validated it against known standards. The panel comprised 228 genes/exons for mutations, 6 regions for translocations, and 56 regions for copy number abnormalities (CNAs). Toward panel validation, targeted sequencing was conducted on 233 patient samples and further validated using clinical fluorescence in situ hybridization (FISH) (translocations), multiplex ligation probe analysis (MLPA) (CNAs), whole genome sequencing (WGS) (CNAs, mutations, translocations) or droplet digital PCR (ddPCR) of known standards (mutations). Canonical IgH translocations were detected in 43.2% of patients by sequencing, and aligned with FISH except for one patient. CNAs determined by sequencing and MLPA for 22 regions were comparable in 103 samples and concordance between platforms was R2=0.969. VAFs for 74 mutations were compared between sequencing and ddPCR with concordance of R2=0.9849. In summary, we have developed a targeted sequencing panel that is as robust or superior to FISH and WGS. This molecular panel is cost effective, comprehensive, clinically actionable and can be routinely deployed to assist risk stratification at diagnosis or post-treatment to guide sequencing of therapies.

PROVIDER: EGAS00001006222 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Validation of a targeted sequencing panel for multiple myeloma

Project description:Here we provide a validated panel for targeted sequencing and analysis of myeloma and other plasma cell dyscrasias to identify the common genomic abnormalities that are diagnostic, prognostic, and clinically actionable. This panel can identify the common immunoglobulin translocations and copy number abnormalities currently detected by FISH, as well as less common translocations, MYC rearrangements, and mutations that are not currently tested for in a standard manner. We hope that adoption of a common sequencing panel will improve patient diagnostics and can be used to assist in risk stratification at diagnosis or post-treatment to guide therapeutic decision making.

| EGAS00001006164 | EGA

NanoString Panel Standard

Project description:RCC files of 17 Cartridges' Panel Standards

| EGAD00010002431 | EGA

Molecular characterization of t(2;14)(q22;q32) and t(6;14)(q25;q32) translocations in mixed myeloid/T lymphoid leukemia patients.

Project description:We characterized two recurrent translocations, i.e. t(2;14)(q22.3;q32) and t(6;14)(q25;q32), in FLT3 positive mixed myeloid/T-cell lymphoid leukemias (MLPA). Both translocations involved BCL11B at 14q32. In cases with t(2;14), the 2q22.3 breakpoint disrupted ZEB2 and produced a ZEB2-BCL11B fusion, a significant ZEB2-BCL11B over-expression with concomitant BCL11B wild type (wt) down-regulation. In cases with t(6;14), the 6q25 breakpoints fell in a 100Kb region where no genes have been mapped thus it not appeared to produce a fusion transcript. As long and short BCL11B isoforms were overexpressed in cases with t(6;14), this could be linked to loss of negative regulatory elements or juxtaposition to strong enhancers/promoters to the intact gene. As BCL11B and ZEB2-BCL11B have identical motifs for DNA and protein interactions, we hypothresized that common downstream target genes might be deregulated. Indeed, gene expression profiling analysis identified a specific signature that characterized this subgroup of MLPA and was unlike any known AML and T-ALL. Exome sequencing did no revealed common variations, thus it was used to investigate 252 candidate genes known to be involved in solid cancer or leukemias. Recurrent mutations in 13 genes, 5 of which were new somatic mutations of DNMT3A, EP300, GNAS, FAT4, and PRRX1 were identified.

2021-12-21 | GSE43417 | GEO

Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery

Project description:The identification of cancer drivers is a major goal of current cancer research. Finding driver genes within large chromosomal events is especially challenging because such alterations encompass many genes. Previously, we demonstrated that zebrafish malignant peripheral nerve sheath tumors (MPNSTs) are highly aneuploid, much like human tumors. In this study, we examined 147 zebrafish MPNSTs by massively parallel sequencing and identified both large and focal copy number alterations (CNAs). Given the low degree of conserved synteny between fish and mammals, we reasoned that comparative analyses of CNAs from fish versus human MPNSTs would enable elimination of a large proportion of passenger mutations, especially on large CNAs. Accordingly, we found less than one third of the human CNA genes were co-gained or co-lost in zebrafish, dramatically narrowing the list of candidate cancer drivers for both focal and large CNAs. We conclude that zebrafish-human comparative analysis represents a powerful, and broadly applicable, tool to enrich for evolutionarily conserved cancer drivers. --- This filing comprises data related to GEO entry GSE23666 ("Highly Aneuploid Zebrafish Malignant Peripheral Nerve Sheath Tumors have Genetic Alterations Similar to Human Cancers"), representing a followup study. 147 pairs of zebrafish (Danio rerio) tumor (MPNST) and normal tail control samples

2013-12-31 | E-GEOD-38397 | biostudies-arrayexpress

Clinical trials verifying the consistency of AmoyDx Essential NGS Panel (Reversible Terminator Sequencing) with local tests

Project description:Interventions: Gold Standard:Histopathological diagnosis;Index test:AmoyDx Essential NGS Panel (Reversible Terminator Sequencing) Primary outcome(s): EGFR 20 insertion mutation;consistency Study Design: Factorial

| 2699936 | ecrin-mdr-crc

Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery

2013-12-31 | GSE38397 | GEO

Uveal melanoma cell lines are representative for their tumour, except cell lines Mel285 and Mel290: the odd two out

Project description:Purpose: In uveal melanoma (UM) research, several cell lines are used in preclinical studies. Because Mel285 and Mel290 do not harbour typical GNAQ or GNA11 hotspot mutations, we aimed at better classifying them and understanding if we could find genetic causes to explain their protein and mRNA expression profiles. Methods: We studied protein and mRNA expression in 14 UM cell lines and determined the presence of Single Nucleotide Variants and small Insertions and Deletions with next generation sequencing and copy number alterations (CNAs) with a single nucleotide polymorphism array. The lists of differentially expressed proteins and genes were merged, and shared lists were created, keeping only the terms with concordant mRNA and protein expression. Enrichment analysis and Gene Set Enrichment Analysis were performed on the shared lists. Results: Mel285 and Mel290 are distinct from the GNA-mutated cell lines and have downregulation of melanosome-related markers. Mel285 and Mel290 lack typical UM mutations but harbour putatively-deleterious variants in four genes each (Mel285: CTNNB1, PPP1R10, LIMCH1, APC; Mel290: ARID1A, PPP1R10, SPG11, RNF43). The upregulated terms in Mel285 and Mel290 did not point to a convincing alternative origin. Mel285 has several CNAs, among which loss of 1p, 3p, partial 3q, 6 and partial 8p, while Mel290 shows 1p loss and chromosome 6 loss. Conclusion: While Mel285 and Mel290 have some CNAs that resemble those in UM, multi-omics analyses show that they belong to a separate group compared to the other analysed UM cell lines. Therefore, they may not be representative models to test potential therapeutic targets for UM.

2024-07-16 | PXD051055 | Pride

Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants in Myeloid Malignancies: Is It Ready for Prime Time?

Project description:Genetic abnormalities including copy number variants (CNVs, such as gains and losses), and gene mutations are important for diagnosis and treatment of myeloid malignances. In a routine clinical setting, somatic gene mutations are detected by targeted next generation sequencing (NGS), but CNVs are commonly detected by conventional chromosome analysis and fluorescence in situ hybridization (FISH). The aim of this proof-of-principle study was to investigate the feasibility of using a targeted NGS assay to simultaneously detect not only somatic mutations, but also CNVs. Here, we sequenced 406 consecutive patients with myeloid malignancies and performed a head-to-head comparison with the results from conventional clinical assays including conventional chromosome analysis and myeloid FISH to detect CNVs. The targeted NGS assay revealed all 120 CNVs detected by myeloid FISH panel including monosomy 5/5q deletions, monosomy 7/7q deletions, trisomy 8, and 20q deletions. Furthermore, the targeted NGS assay also detected 605 CNVs outsides targeted regions of the myeloid FISH panel, which were revealed by conventional cytogenetic testing. The targeted NGS assay achieved 100% concordance with the myeloid FISH for detection of these common myeloid CNVs, with a high clinical sensitivity (> 99%) and specificity (>99%). The lower limit of detection by the myeloid FISH and the targeted NGS assay was similar and was generally 5% variant allele fraction for DNA. This proof-of-principle study demonstrated that the targeted NGS assay can simultaneously detect both common myeloid CNVs and somatic mutations, which can provide more comprehensive genetic profiling for patients with myeloid malignancies using a single assay.

2021-01-29 | GSE165733 | GEO

Bacterial WGS validation panel

Project description:Bacterial WGS validation panel

| PRJNA341407 | ENA

PAGE: Global Reference Panel

Project description:PAGE: Global Reference Panel

| PRJNA302341 | ENA